News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Obecure Completes Treatment of Patients in Phase II Obesity Trial


6/25/2007 1:32:00 PM

RAMAT GAN, Israel--(BUSINESS WIRE)--Obecure announced today that the last patient to be enrolled in the company’s Phase II clinical trial for obesity has completed treatment. The double-blinded, placebo-controlled, dose-ranging study enrolled 281 patients with a BMI ranging from 30-40 at 20 clinical centers across the U.S. Subjects were randomized into one of four treatment arms comparing placebo with 16 mg., 32 mg., and 48 mg. daily doses of the company’s OBE101 drug candidate. Treatment was administered orally, twice daily, for a duration of 12 weeks. The company expects to present top-level results of the trial in the early fall.

Read at BioSpace.com

comments powered by Disqus
Obecure
 
 
Obesity

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES